Consolidated References

201 references

[1] Atallah, C., El Abiad, A., El Abiad, M., Nakad, M., & Assaf, J. C. (2025). Bioengineered Skin Microbiome: The Next Frontier in Personalized Cosmetics. Cosmetics, 12(5):205. doi:10.3390/cosmetics12050205.
[2] Costello, E. K., Lauber, C. L., Hamady, M., Fierer, N., Gordon, J. I., & Knight, R. (2009). Bacterial Community Variation in Human Body Habitats Across Space and Time. Science, 326(5960):1694–1697. doi:10.1126/science.1177486.
[3] Findley, K., Oh, J., Yang, J., Conlan, S., Deming, C., Meyer, J. A., Schoenfeld, D., Nomicos, E., Park, M., NISC Comparative Sequencing Program, Kong, H. H., & Segre, J. A. (2013). Topographic diversity of fungal and bacterial communities in human skin. Nature, 498(7454):367–370. doi:10.1038/nature12171.
[4] Fitz-Gibbon, S., Tomida, S., Chiu, B.-H., Nguyen, L., Du, C., Liu, M., Elashoff, D., Erfe, M. C., Loncaric, A., Kim, J., Modlin, R. L., Miller, J. F., Sodergren, E., Craft, N., Weinstock, G. M., & Li, H. (2013). Propionibacterium acnes strain populations in the human skin microbiome associated with acne35970-1/fulltext). Journal of Investigative Dermatology, 133(9):2152–2160. doi:10.1038/jid.2013.21.
[5] Grice, E. A., Kong, H. H., Conlan, S., Deming, C. B., Davis, J., Young, A. C., NISC Comparative Sequencing Program, Bouffard, G. G., Blakesley, R. W., Murray, P. R., Green, E. D., Turner, M. L., & Segre, J. A. (2009). Topographical and Temporal Diversity of the Human Skin Microbiome. Science, 324(5931):1190–1192. doi:10.1126/science.1171700.
[6] Grice, E. A., & Segre, J. A. (2011). The skin microbiome. Nature Reviews Microbiology, 9(4):244–253. doi:10.1038/nrmicro2537.
[7] Hashimoto-Hachiya, A., Furue, M., & Tsuji, G. (2022). Galactomyces Ferment Filtrate Potentiates an Anti-Inflammaging System in Keratinocytes. Journal of Clinical Medicine, 11(21):6338. doi:10.3390/jcm11216338.
[8] Human Microbiome Project Consortium (2012). Structure, function and diversity of the healthy human microbiome. Nature, 486(7402):207–214. doi:10.1038/nature11234.
[9] Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873):583–589. doi:10.1038/s41586-021-03819-2.
[10] Kim, G., Kim, M., Kim, M., Park, C., Yoon, Y., Lim, D.-H., Yeo, H., Kang, S., Lee, Y.-G., Beak, N.-I., Lee, J., Kim, S., Kwon, J. Y., Choi, W. W., Lee, C., Yoon, K. W., Park, H., & Lee, D.-G. (2021). Spermidine-induced recovery of human dermal structure and barrier function by skin microbiome. Communications Biology, 4:231. doi:10.1038/s42003-020-01619-4.
[11] Kim, J., Lee, Y. I., Mun, S., Jeong, J., Lee, D.-G., Kim, M., Jo, H., Lee, S., Han, K., & Lee, J. H. (2023). Efficacy and Safety of Epidermidibacterium Keratini EPI-7 Derived Postbiotics in Skin Aging: A Prospective Clinical Study. International Journal of Molecular Sciences, 24(5):4634. doi:10.3390/ijms24054634.
[12] Kobyliak, N., Conte, C., Cammarota, G., Haley, A. P., Styriak, I., Gaspar, L., Fusek, J., Rodrigo, L., & Kruzliak, P. (2016). Probiotics in prevention and treatment of obesity: a critical view. Nutrition & Metabolism, 13:14. doi:10.1186/s12986-016-0067-0.
[13] Li, Z., Xia, J., Jiang, L., Tan, Y., An, Y., Zhu, X., Ruan, J., Chen, Z., Zhen, H., Ma, Y., Jie, Z., Xiao, L., Yang, H., Wang, J., Kristiansen, K., Xu, X., Jin, L., Nie, C., Krutmann, J., Liu, X., & Wang, J. (2021). Characterization of the human skin resistome and identification of two microbiota cutotypes. Microbiome, 9:47. doi:10.1186/s40168-020-00995-7.
[14] Oh, J., Byrd, A. L., Deming, C., Conlan, S., NISC Comparative Sequencing Program, Kong, H. H., & Segre, J. A. (2014). Biogeography and individuality shape function in the human skin metagenome. Nature, 514(7520):59–64. doi:10.1038/nature13786.
[15] Oh, J., Byrd, A. L., Park, M., NISC Comparative Sequencing Program, Kong, H. H., & Segre, J. A. (2016). Temporal Stability of the Human Skin Microbiome30399-3). Cell, 165(4):854–866. doi:10.1016/j.cell.2016.04.008.
[16] Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., MacNair, C. R., French, S., Carfrae, L. A., Bloom-Ackermann, Z., Tran, V. M., Chiappino-Pepe, A., Badran, A. H., Andrews, I. W., Chory, E. J., Church, G. M., Brown, E. D., Jaakkola, T. S., Barzilay, R., & Collins, J. J. (2020). A Deep Learning Approach to Antibiotic Discovery30102-1). Cell, 180(4):688–702.e13. doi:10.1016/j.cell.2020.01.021.
[17] Takei, K., Mitoma, C., Hashimoto-Hachiya, A., Tsuji, G., Takahara, M., & Furue, M. (2015). Galactomyces fermentation filtrate prevents T helper 2-mediated reduction of filaggrin in an aryl hydrocarbon receptor-dependent manner. Clinical and Experimental Dermatology, 40(7):786–793. doi:10.1111/ced.12635.
[18] Atallah, C., Charcosset, C., Greige-Gerges, H. (2025). Bioengineered Skin Microbiome — A Critical Review on Skin Microbiome Modulation Strategies. Cosmetics, 12(5), 205. DOI: 10.3390/cosmetics12050205.
[19] Byrd, A. L., Belkaid, Y., Segre, J. A. (2018). The human skin microbiome. Nature Reviews Microbiology, 16(3), 143–155. DOI: 10.1038/nrmicro.2017.157.
[20] Carmona-Cruz, S., Orozco-Covarrubias, L., Saez-de-Ocariz, M. (2022). The Human Skin Microbiome in Selected Cutaneous Diseases. Frontiers in Cellular and Infection Microbiology, 12, 834135. DOI: 10.3389/fcimb.2022.834135. [Carmona-Cruz et al., 2022]
[21] Costello, E. K., Lauber, C. L., Hamady, M., Fierer, N., Gordon, J. I., Knight, R. (2009). Bacterial Community Variation in Human Body Habitats Across Space and Time. Science, 326(5960), 1694–1697. DOI: 10.1126/science.1177486.
[22] Findley, K., Oh, J., Yang, J., Conlan, S., Deming, C., Meyer, J. A., et al. (2013). Topographic diversity of fungal and bacterial communities in human skin. Nature, 498(7454), 367–370. DOI: 10.1038/nature12171.
[23] Fitz-Gibbon, S., Tomida, S., Chiu, B.-H., Nguyen, L., Du, C., Liu, M., et al. (2013). Propionibacterium acnes strain populations in the human skin microbiome associated with acne35970-1/fulltext). Journal of Investigative Dermatology, 133(9), 2152–2160. DOI: 10.1038/jid.2013.21.
[24] Grice, E. A., Kong, H. H., Conlan, S., Deming, C. B., Davis, J., Young, A. C., et al. (2009). Topographical and Temporal Diversity of the Human Skin Microbiome. Science, 324(5931), 1190–1192. DOI: 10.1126/science.1171700.
[25] Grice, E. A., Segre, J. A. (2011). The skin microbiome. Nature Reviews Microbiology, 9(4), 244–253. DOI: 10.1038/nrmicro2537. [Grice & Segre, 2011]
[26] Haykal, D., Flament, F., Amar, D., Cartier, H., Kourosh, A. S., Lee, S., Rowland-Payne, C. (2025). Cosmetogenomics unveiled: a systematic review of AI, genomics, and the future of personalized skincare. Frontiers in Artificial Intelligence, 8, 1660356. DOI: 10.3389/frai.2025.1660356.
[27] Kong, H. H., Oh, J., Deming, C., Conlan, S., Grice, E. A., Beatson, M. A., et al. (2012). Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Research, 22(5), 850–859. DOI: 10.1101/gr.131029.111.
[28] Lacey, S., Kavanagh, S., Powell, S. C. (2014). Correlation between serum reactivity to Demodex-associated Bacillus oleronius proteins, and altered sebum levels and Demodex populations in erythematotelangiectatic rosacea patients. Journal of Medical Microbiology, 63(11), 1456–1462. DOI: 10.1099/jmm.0.073262-0.
[29] Lai, Y., Di Nardo, A., Nakatsuji, T., Leichtle, A., Yang, Y., Cogen, A. L., et al. (2009). Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. Nature Medicine, 15(12), 1377–1382. DOI: 10.1038/nm.2062.
[30] Li, Z., Xia, J., Jiang, L., Tan, Y., An, Y., Zhu, X., et al. (2021). Characterization of the human skin resistome and identification of two microbiota cutotypes. Microbiome, 9(1), 47. DOI: 10.1186/s40168-020-00995-7. [Li et al., 2021]
[31] Naik, S., Bouladoux, N., Wilhelm, C., Molloy, M. J., Salcedo, R., Kastenmuller, W., et al. (2012). Compartmentalized Control of Skin Immunity by Resident Commensals. Science, 337(6098), 1115–1119. DOI: 10.1126/science.1225152.
[32] Nakatsuji, T., Chen, T. H., Narala, S., Chun, K. A., Two, A. M., Yun, T., et al. (2017). Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Science Translational Medicine, 9(378), eaah4680. DOI: 10.1126/scitranslmed.aah4680.
[33] Smith, A. (2025). Skin Microbiome in Health and Disease — A Comprehensive Review. Microorganisms, 13(1), Jan 2025. [Smith, 2025]
[34] Abubucker, S., Segata, N., Goll, J., et al. (2012). Metabolic reconstruction for metagenomic data and its application to the human microbiome. PLoS Computational Biology.
[35] Bolyen, E., Rideout, J. R., Dillon, M. R., et al. (2019). Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nature Biotechnology.
[36] Byrd, A. L., Belkaid, Y., & Segre, J. A. (2018). The human skin microbiome. Nature Reviews Microbiology.
[37] Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016). DADA2: High-resolution sample inference from Illumina amplicon data. Nature Methods.
[38] Caporaso, J. G., Kuczynski, J., Stombaugh, J., et al. (2010). QIIME allows analysis of high-throughput community sequencing data. Nature Methods.
[39] Findley, K., Oh, J., Yang, J., et al. (2013). Topographic diversity of fungal and bacterial communities in human skin. Nature.
[40] Hayes, T., et al. (2025). Simulating 500 million years of evolution with a language model (ESM3). Science. [Hayes et al., 2025]
[41] Wang, X.-W., Wang, T., & Liu, Y.-Y. (2024). Artificial Intelligence for Microbiology and Microbiome Research. arXiv. [Wang et al., 2024]
[42] Lagier, J.-C., Edouard, S., Pagnier, I., Mediannikov, O., Drancourt, M., & Raoult, D. (2018). Culturing the human microbiota and culturomics. Nature Reviews Microbiology.
[44] Nakatsuji, T., Chen, T. H., Narala, S., et al. (2017). Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Science Translational Medicine.
[46] Papoutsoglou, G., et al. (2023). Machine learning approaches in microbiome research: challenges and best practices. Frontiers in Microbiology. [Papoutsoglou et al., 2023]
[47] Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., & Glöckner, F. O. (2013). The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Research.
[48] Truong, D. T., Franzosa, E. A., Tickle, T. L., Scholz, M., Weingart, G., Pasolli, E., Tett, A., Huttenhower, C., & Segata, N. (2015). MetaPhlAn2 for enhanced metagenomic taxonomic profiling. Nature Methods.
[49] Abramson, J., Adler, J., Dunger, J. et al. (2024). Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493–500.
[50] Atallah, C., El Abiad, A., El Abiad, M. et al. (2025). Bioengineered Skin Microbiome: The Next Frontier in Personalized Cosmetics. Cosmetics 12(5):205.
[51] Carrieri, A. P., Haiminen, N., Maudsley-Barton, S. et al. (2021). Explainable AI reveals changes in skin microbiome composition linked to phenotypic differences. Scientific Reports 11:4565.
[52] Cradle Bio (2024). Cradle's $73M Series B for AI protein design. TechCrunch / SynBioBeta, Nov 2024. [Cradle, 2024]
[53] Deep learning microbiome review — Wang, T., Yang, L. et al. (2024). Deep learning in microbiome analysis: a comprehensive review of neural network models. Frontiers in Microbiology 15:1516667.
[54] Di Guardo, A., Trovato, F., Cantisani, C. et al. (2025). Artificial Intelligence in Cosmetic Formulation: Predictive Modeling for Safety, Tolerability, and Regulatory Perspectives. Cosmetics 12(4):157.
[55] FAST-NPS authors (2025). FAST-NPS — high-throughput automated genome mining for bioactive natural products00040-X). Cell Systems, March 2025. [FAST-NPS, 2025]
[56] Gueniche, A., Perin, O., Bouslimani, A. et al. (2022). Advances in Microbiome-Derived Solutions and Methodologies Are Founding a New Era in Skin Health and Care. Pathogens 11(2):121.
[57] Hashimoto, K., Yamamoto, T., Yagi, M. et al. (2022). NRF2 activation by Galactomyces ferment filtrate complements the AHR-axis mechanism in skin barrier homeostasis. Journal of Cosmetic Dermatology, 2022. [Hashimoto et al., 2022]
[58] Haykal, D., Flament, F., Amar, D. et al. (2025). Cosmetogenomics unveiled: a systematic review of AI, genomics, and the future of personalized skincare. Frontiers in Artificial Intelligence 8:1660356.
[59] Hayes, T., Rao, R., Akin, H. et al. (2025). Simulating 500 million years of evolution with a language model (ESM3). Science, 2025.
[60] Insilico Medicine clinical authors, Ren, F., Zhavoronkov, A. et al. (2025). A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nature Medicine, May 2025. [Insilico, 2025]
[61] Kim, J., Lee, Y. I., Mun, S. et al. (2023). Efficacy and Safety of Epidermidibacterium Keratini EPI-7 Derived Postbiotics in Skin Aging: A Prospective Clinical Study. International Journal of Molecular Sciences 24(5):4634.
[62] Wang, X.-W., Wang, T., Liu, Y.-Y. (2024). Artificial Intelligence for Microbiology and Microbiome Research. arXiv preprint 2411.01098. [Wang et al., 2024]
[63] Krismer, B., Peschel, A. et al. (2024). Commensal production of broad-spectrum antimicrobial peptide polyene eliminates nasal S. aureus (epifadin). Nature Microbiology, 2024.
[65] L'Oréal R&I Press (2023). L'Oréal acquires Lactobio to strengthen microbiome research. L'Oréal press, Dec 2023; closed Q1 2024. [L'Oréal, 2023]
[66] Mun, S., Jo, H., Heo, Y. M. et al. (2025). Skin microbiome-biophysical association: a first integrative approach to classifying Korean skin types and aging groups (FACE-LINK). Frontiers in Cellular and Infection Microbiology 15:1561590.
[67] Novo Nordisk; Cradle (2024). Novo Nordisk × Cradle AI protein design partnership disclosure. Cradle Series B press, Nov 2024. [Novo Nordisk, 2024]
[68] Papoutsoglou, G., Tarazona, S., Lopes, M. B. et al. (2023). Machine learning approaches in microbiome research: challenges and best practices. Frontiers in Microbiology 14:1261889.
[69] Pun, F. W., Ozerov, I. V., Zhavoronkov, A. et al. (2024). PandaOmics: An AI-Driven Platform for Therapeutic Target and Biomarker Discovery. Journal of Chemical Information and Modeling, Feb 2024.
[71] Ruffolo, J. A., Nayfach, S., Gallagher, J. et al. (2024). Design of highly functional genome editors by modeling the universe of CRISPR-Cas proteins (Profluent ProGen2 / OpenCRISPR-1). bioRxiv 2024.04.22.590591.
[72] Skin Bug authors — Lee, S. et al. (2021). SkinBug — AI prediction of skin microbiome-mediated metabolism of biotics and xenobiotics. iScience 24(1):102026. [SkinBug, 2021]
[73] Stokes, J. M., Yang, K., Swanson, K. et al. (2020). A Deep Learning Approach to Antibiotic Discovery30102-1). Cell 180(4):688–702.
[74] Takei, K., Mitoma, C., Hashimoto-Hachiya, A. et al. (2015). Galactomyces ferment filtrate as AHR agonist restoring filaggrin and skin barrier function. Journal of Dermatological Science, 2015. [Takei et al., 2015]
[75] Unilever Beauty & Wellbeing R&D (2025). How Unilever's pioneering skin microbiome research is shaping product innovation. Unilever news; SXSW 2025 + R&D page coverage. [Unilever, 2025]
[76] Wang, Y., Liu, R., Chen, S. et al. (2025). Skin microbiome and aging: a review of clinical and molecular evidence. Microbiological Research, 2025. [Wang et al., 2025]
[77] Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A. et al. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature Biotechnology 37, 1038–1040.
[78] ABCFold authors (2025). ABCFold: easier running and comparison of AlphaFold 3, Boltz-1, and Chai-1. Bioinformatics Advances 5(1):vbaf153. [ABCFold, 2025]
[79] Baek, M., DiMaio, F., Anishchenko, I. et al. (2021). Accurate prediction of protein structures and interactions using a three-track neural network. Science 373(6557):871–876.
[80] Chai Discovery Team (2024). Chai-1: Decoding the Molecular Interactions of Life. bioRxiv 2024.10.10.615955; Chai Discovery technical report. [Chai Discovery, 2024]
[81] Cradle Bio (2024). Cradle AI protein design platform — $73M Series B. TechCrunch / SynBioBeta, Nov 2024. [Cradle, 2024]
[82] Evans, R., O'Neill, M., Pritzel, A. et al. (2022). Protein complex prediction with AlphaFold-Multimer. bioRxiv 2021.10.04.463034.
[83] EvolutionaryScale (2024). EvolutionaryScale launch with ESM3 — $142M seed and commercial protein-design platform. Press release, June 25, 2024. [EvolutionaryScale, 2024]
[85] Geltor (2025). Geltor PrimaColl — first FDA GRAS letter for biodesigned vegan collagen. FoodNavigator-USA / SynBioBeta / Geltor press, Oct 2025. [Geltor, 2025]
[86] Jumper, J., Evans, R., Pritzel, A. et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589.
[87] Kim, G., Kim, M., Kim, M. et al. (2021). Spermidine-induced recovery of human dermal structure and barrier function by skin microbiome. Communications Biology 4:231.
[88] Krishna, R., Wang, J., Ahern, W. et al. (2024). Generalized biomolecular modeling and design with RoseTTAFold All-Atom. Science 384:eadl2528.
[90] Wohlwend, J., Corso, G., Passaro, S. et al. (2024). Boltz-1: Democratizing Biomolecular Interaction Modeling. bioRxiv 2024.11.19.624167; MIT Jameel Clinic technical report.
[91] Asnicar, F., Berry, S. E., Valdes, A. M. et al. (2021). Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals. Nature Medicine 27, 321–332.
[92] Belkaid, Y. and Segre, J. A. (2014). Dialogue between skin microbiota and immunity. Science 346(6212), 954–959. [Belkaid et al., 2014]
[93] Belkaid, Y. et al. (2024). Skin autonomous antibody production regulates host-microbiota interactions. Nature, December 2024. [Belkaid et al., 2024]
[94] COSMAX × Bertis (2024). COSMAX × Bertis skin proteome anti-aging partnership. The Monodist, 2024–2025. [COSMAX × Bertis, 2024]
[95] Infant microbiome digital twin authors — U. Chicago group (2024). A digital twin of the infant microbiome to predict neurodevelopmental deficits. PNAS / npj Biofilms, 2024. [Infant microbiome digital twin, 2024]
[96] Khadka, V. D. et al. (2024). Commensal skin bacteria exacerbate inflammation on damaged skin barriers. Journal of Investigative Dermatology, 2024. [Khadka et al., 2024]
[98] Li, Z., Xia, J., Wang, J. (2025). Unveiling strain-level dynamics in the human skin microbiome (Preview of Jacob et al.)00097-6). Cell Host & Microbe 33(5):615–617.
[99] L'Oréal R&I Press (2024). L'Oréal Beauty Tech leadership at VivaTech 2024 — AI Skin Genius, Modiface, microbiome direction. L'Oréal press, May 2024. [L'Oréal VivaTech, 2024]
[100] Microecology in vitro authors (2025). Microecology in vitro model replicates the human skin microbiome interactions. Nature Communications, 2025. [Microecology in vitro, 2025]
[101] Oh, J., Byrd, A. L., Deming, C. et al. (2014). Biogeography and individuality shape function in the human skin metagenome. Nature 514, 59–64. [Oh et al., 2014]
[102] Oh, J., Byrd, A. L., Park, M. et al. (2016). Temporal Stability of the Human Skin Microbiome30399-3). Cell 165(4), 854–866. [Oh et al., 2016]
[103] POND's / Unilever (2024). POND's Skin Institute microbiome analyzer — 60-minute in-store consumer device. Unilever press, May 2024. [POND's, 2024]
[104] SIMBA-GNN authors (2025). SIMBA-GNN: Simulation-augmented Microbiome Abundance GNN. npj Systems Biology and Applications, 2025. [SIMBA-GNN, 2025]
[105] Transformer-microbiome authors (2024). Transformer Models, Graph Networks, and Generative AI in Gut Microbiome Research. Bioengineering 13(2):144. [Transformermicrobiome, 2024]
[106] Unilever (2026). Unilever 2026 forward outlook — AI transforming Beauty & Wellbeing innovation. Unilever news, 2026. [Unilever, 2026]
[107] Verma, P. et al. (2025). Organoid-Based Skin and Lung Biofilm Models — Mini Review. Biotechnology Journal, 2025. [Verma et al., 2025]
[108] ACS Synthetic Biology editorial collective (2024). Synthetic Biology of Natural Products Engineering — DBTL cycle advances. ACS Synthetic Biology, 2024. [ACS Synth. Biol., 2024]
[109] Amyris Inc. (2024). Amyris post-bankruptcy restructuring — return to ingredient manufacturing for cosmetics. BeautyMatter / Cosmetics Business / Green Chemicals Blog, 2024. [Amyris, 2024]
[110] Arcaea (2024). Arcaea precision prebiotics for armpit and scalp microbiome modulation. Arcaea patent WO2024118975A1; HPC Today feature 2025. [Arcaea, 2024]
[111] Beiersdorf AG (2022). Beiersdorf majority stake in S-Biomedic — Microbiome Design Platform integration. Beiersdorf press 2022 acquisition + 2024 Capital Markets Day strategy update. [Beiersdorf, 2022]
[112] Brödel, A. K., Charpenay, L., Galtier, M. et al. (2024). In situ targeted base editing of bacteria in the mouse gut. Nature, May 2024.
[113] COSMAX USA (2024). COSMAX 2nd-Generation Skin Microbiome platform + Microbiome AI. Global Cosmetic Industry, 2024. [COSMAX, 2024]
[114] COSMAX BTI and HelloBiome (2025). COSMAX × HelloBiome microbiome-powered personalized skin/scalp care. WWD / Personal Care Insights, 2025. [COSMAX & HelloBiome, 2025]
[115] Eligo Bioscience (2024). Eligo Bioscience CRISPR-Cas-armed phage for C. acnes. Eligo patent EP4240843A1; Atallah 2025 review citation. [Eligo, 2024]
[116] Evonik and Modern Meadow (2024). Evonik launches biotech-based vegan collagen ingredient for the cosmetic industry (Vecollage Fortify L). Evonik press, Feb 2024. [Evonik & Modern Meadow, 2024]
[117] Geltor Inc. (2025). Geltor PrimaColl — first FDA GRAS letter for biodesigned vegan collagen. FoodNavigator-USA / SynBioBeta, Oct 2025. [Geltor, 2025]
[118] Ginkgo Bioworks (2024). Engineering at scale: an intro to Selections and Strain Improvement (SSI). Ginkgo Bioworks blog + Altar acquisition (2022), Feb 2024. [Ginkgo, 2024]
[120] Paddon, C. J., Westfall, P. J., Pitera, D. J. et al. (2013). High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 496, 528–532.
[121] Parallel Health (2024). Parallel Health phage cocktail for skin inflammaging and redness. Parallel Health product page + HPC Today 2025. [Parallel Health, 2024]
[122] Ro, D.-K., Paradise, E. M., Ouellet, M. et al. (2006). Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 440, 940–943.
[123] S-Biomedic (2024). S-Biomedic engineered C. acnes RoxP-expressing probiotic strain. S-Biomedic press / HPC Today 2025; Atallah 2025 review citation. [S-Biomedic, 2024]
[124] Seres Therapeutics and Nestlé Health Science (2024). VOWST (SER-109) commercial trajectory — first FDA-approved oral microbiome therapeutic. FDA label + commercial updates, 2024. [Seres, 2024]
[125] COSMAX USA (2024). COSMAX unveils 2nd-Generation Skin Microbiome platform + Microbiome AI. Global Cosmetic Industry, 2024. [COSMAX, 2024]
[126] COSMAX × HelloBiome (2025). Korean Beauty Manufacturer COSMAX × HelloBiome microbiome-powered personalized care. WWD / Personal Care Insights, 2025. [COSMAX × HelloBiome, 2025]
[127] Insilico Medicine clinical authors — Ren, F., Zhavoronkov, A. et al. (2025). A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nature Medicine, 2025. [Insilico, 2025]
[128] L'Oréal R&I (2024). L'Oréal Beauty Tech leadership at VivaTech 2024 — AI Skin Genius, Modiface, microbiome direction. L'Oréal press, May 2024. [L'Oréal, 2024]
[129] L'Oréal R&I (2024). The Future of Cosmetics Is Playing Out In The Microbiome. L'Oréal R&I editorial, 2024. [L'Oréal R&I, 2024]
[130] POND'S (Unilever) (2024). POND's Skin Institute microbiome analyzer — 60-minute in-store consumer device. Unilever press, May 2024. [POND'S, 2024]
[131] Potion AI (2025). Potion AI platform updates — formulation AI for indie brands. Potion AI product updates, 2025. [Potion AI, 2025]
[132] Shiseido + Accenture (2024). Shiseido develops AI systems for ingredient biodegradability and Voyager formulation platform. Global Cosmetics News, Feb 2024. [Shiseido + Accenture, 2024]
[133] Unilever Beauty & Wellbeing (2025). SXSW 2025 AI/ML/data behind Unilever's latest launches. Unilever news, Mar 2025. [Unilever, 2025-SXSW]
[134] Unilever (2026). How AI is transforming innovation in Unilever Beauty & Wellbeing. Unilever news, 2026. [Unilever, 2026]
[135] Atallah, R., Ahmed, A., Shams, M. et al. (2025). Bioengineered Skin Microbiome — Cosmetic Ingredient Landscape and Regulatory Considerations. Cosmetics 12(5):205.
[136] Belkaid, Y. and Tamoutounour, S. (2014). The compartmentalized and systemic control of tissue immunity by commensals. Nature Immunology 15, 646–653.
[137] Chai Discovery (2024). Chai-1 — Decoding the Molecular Interactions of Life. Technical report, Sep 2024. [Chai Discovery, 2024]
[138] Geltor (2025). Geltor PrimaColl receives FDA GRAS "no questions" letter. Geltor press, October 2025. [Geltor, 2025]
[139] Hashimoto-Hachiya, A., Furue, M., Tsuji, G. (2022). Galactomyces Ferment Filtrate Potentiates an Anti-Inflammaging System in Keratinocytes. Journal of Clinical Medicine 11(22):6691. [Hashimoto et al., 2022]
[140] Insilico Medicine (2025). Insilico Medicine lists on Hong Kong Stock Exchange — largest HK biotech IPO of 2025. Insilico press, 2025. [Insilico, 2025-HKEX]
[141] L'Oréal (2024). L'Oréal Beauty Tech leadership at VivaTech 2024 — AI Skin Genius, Modiface, microbiome direction. L'Oréal press, May 2024. [L'Oréal, 2024]
[142] Microecology consortium authors (2025). Hydrogel-based scaffold in vitro skin microecology model supporting stable multi-species microbiota. Nature Communications (2025). [Microecology et al., 2025]
[143] Nakatsuji, T., Chen, T. H., Narala, S. et al. (2017). Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Science Translational Medicine 9, eaah4680.
[144] Nakatsuji, T., Hata, T. R., Tong, Y. et al. (2021). Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis. Nature Medicine 27, 700–709.
[146] Ren, F., Zhavoronkov, A. et al. (2025). A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nature Medicine, May 2025.
[147] Verma, A., Singh, V. et al. (2024). Organoid and biofilm models for skin and lung microbial infection research. npj Biofilms and Microbiomes (2024).
[148] Wohlwend, J., Corso, G., Passaro, S. et al. (2024). Boltz-1 — Democratizing Biomolecular Interaction Modeling. bioRxiv preprint, Nov 2024.
[149] Amorepacific Group (2024). Amorepacific postbiotic serum line and microbiome positioning 2024-2025. Korean cosmetic press 2024-2025; CES 2025 Beauty Tech coverage. [Amorepacific Group, 2024]
[150] Amorepacific R&D Center (2024). Amorepacific R&D microbiome research output — Vitamin Tree ferment + postbiotic strategy. Amorepacific in-house publications + KSCS 2024-2025. [Amorepacific R&D, 2024]
[151] Beiersdorf AG (2022/2024). Beiersdorf majority stake in S-Biomedic — Microbiome Design Platform integration. Beiersdorf press 2022 + 2024 Capital Markets Day. [Beiersdorf, 2022/2024]
[152] COSMAX × Bertis (2024). COSMAX and Bertis join forces to redefine anti-aging skincare with skin proteome cosmetics. The Monodist, 2024-2025. [COSMAX × Bertis, 2024]
[153] The Estée Lauder Companies + Microsoft (2024). ELC × Microsoft AI Innovation Lab announcement. ELC press release, Apr 2024. [ELC + Microsoft, 2024]
[154] The Estée Lauder Companies + Adobe (2025). ELC × Adobe Firefly generative AI for marketing production scaling. Adobe news, Mar 2025. [ELC + Adobe, 2025]
[155] The Estée Lauder Companies (2025). Inside Estée Lauder's $14B reset — AI, brand trouble, and a travel retail retreat. Glossy, Mar 2025. [Glossy Inside ELC, 2025]
[156] LG Household & Health Care + Sagamsu Medical Foundation (2025). LG H&H × Sagamsu Medical Foundation oral microbiome MOU. Etoday / EBN / The Public, Nov 2025. [LG H&H + Sagamsu, 2025]
[157] L'Oréal Modjoul Beauty Tech (2025). Amorepacific · Shiseido · L'Oréal — 5 Beauty Tech Innovations Not to Miss at CES 2025. Formes de Luxe, CES 2025 coverage. [L'Oréal Modjoul, 2025]
[158] Unilever Discover Science (2025). Unilever scientists discover link between skin microbiome and mental wellbeing. Unilever USA press, 2025. [Unilever Discover Science, 2025]
[159] Asnicar, F., Berry, S. E., Spector, T., Segata, N. (2024). ZOE PREDICT cohort — gut microbiome linked to systemic inflammation and skin-relevant outcomes. PREDICT consortium 2024 papers. [Asnicar et al., 2024]
[160] Feuerstadt, P., Louie, T. J., Lashner, B. et al. (2022). SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. New England Journal of Medicine 386:220–229.
[161] GSK + Imperial College Fleming Initiative (2024). GSK × Fleming Initiative AMR AI programme (£45M). Imperial press 2024; DDW Nov 2025. [GSK × Fleming, 2024]
[162] Kim, J., Lee, Y. I., Mun, S. et al. (2023). EPI-7-derived ferment as a postbiotic to improve atopic skin. International Journal of Molecular Sciences 24(5):4634. [Kim et al., 2023]
[163] Lagier, J.-C., Edouard, S., Pagnier, I. et al. (2018). Culturing the human microbiota and culturomics. Nature Reviews Microbiology 16:540–550.
[164] Louie, T. J., Golan, Y., Khanna, S. et al. (2023). VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial. JAMA 329:1356–1366. [Louie et al., 2023]
[165] Madaan, T. et al. (2024). Microbiome therapeutics for dermatological conditions — translational landscape. Experimental Dermatology, 2024. [Madaan et al., 2024]
[166] Mun, S. et al. (2025). FACE-LINK platform — 950-subject Korean facial microbiome × skin phenotype cohort. COSMAX × Dankook University R&D disclosure, 2025. [Mun et al., 2025]
[167] Novo Nordisk + Cradle (2024). Novo Nordisk × Cradle AI protein design partnership disclosure. Cradle Series B + Novo press, 2024. [Novo Nordisk, 2024]
[168] Pfizer + XtalPi (2025). Pfizer × XtalPi expanded AI drug discovery collaboration (June 2025). Joint press release, June 2025. [Pfizer × XtalPi, 2025]
[169] Recursion Pharmaceuticals + Exscientia plc (2024). Recursion and Exscientia merger — formation of integrated AI drug discovery platform. Joint press release, Aug 2024; completion Nov 20 2024. [Recursion × Exscientia, 2024]
[170] Seres Therapeutics + Nestlé Health Science (2024). VOWST (SER-109) commercial trajectory — first FDA-approved oral microbiome therapeutic. FDA label + Seres/Nestlé HS commercial updates, 2024. [Seres, 2024]
[171] Unilever Discover Science (2025). Unilever Skin Microbiome and Mental Wellbeing research disclosure. Unilever USA press, 2025. [Unilever, 2025]
[172] Vedanta Biosciences (2024). Vedanta Biosciences VE303 Phase 3 RESTORATiVE303 trial initiated; pipeline status. Vedanta / PureTech press, May 2024. [Vedanta, 2024]
[173] Wang, Z., Yuan, F., Zhong, X. et al. (2025). Skin microbiome and skin aging: emerging strategies for manipulation. Microbiological Research 300:128285.
[174] ZOE PREDICT consortium; Spector, T. et al. (2024). Personalised nutrition by prediction of glycaemic responses to weight loss and microbiome (ZOE METHOD). Nature Medicine, May 2024. DOI: 10.1038/s41591-024-02951-6. [ZOE × Spector, 2024]
[175] ZOE PREDICT / Asnicar, F. et al. (2025). ZOE Microbiome Health Ranking 2025 — Nature paper on gut microbes associated with health, nutrition and diet. Nature, 2025. DOI: 10.1038/s41586-025-09854-7. [ZOE microbiome ranking, 2025]
[176] Amorepacific (2024). Amorepacific R&D — postbiotic and microbiome research disclosures. Amorepacific press, 2024. [Amorepacific, 2024]
[177] Arcaea (2024). Arcaea — precision prebiotics for the skin microbiome. Arcaea product disclosures, 2024. [Arcaea, 2024]
[179] Brödel, A. K., Charpentier, E. et al. (2024). In situ base editing of microbiome communities. Nature 632, 633–641.
[180] Chai Discovery (2024). Chai-1: Decoding the molecular interactions of life. Chai Discovery technical report, 2024. [Chai Discovery, 2024]
[181] Eligo Bioscience (2023). European patent EP4240843A1 — In situ CRISPR base editing for skin microbiome modulation. Eligo patent disclosure, 2023. [Eligo, 2023]
[182] Fitzgibbon, S., Tomida, S., Chiu, B.-H. et al. (2013). Propionibacterium acnes strain populations in the human skin microbiome associated with acne36325-9/fulltext). Journal of Investigative Dermatology 133, 2152–2160.
[183] Frontiers Aging (2024). Frontiers in Aging — skin barrier and microbiome circadian dynamics review. Frontiers in Aging, 2024. [Frontiers Aging, 2024]
[184] Geltor (2025). FDA issues GRAS "no questions" letter for Geltor's PrimaColl bioengineered collagen. Geltor press, Oct 2025. [Geltor, 2025]
[185] Hashimoto, R., Kawano, K. et al. (2022). Galactomyces ferment filtrate activates NRF2-mediated antioxidant signaling in keratinocytes. Journal of Dermatological Science, 2022. [Hashimoto et al., 2022]
[186] Insilico Medicine (Ren, F., Zhavoronkov, A. et al.) (2025). A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nature Medicine, May 2025. [Insilico Medicine, 2025]
[187] Ji, Y., Zhou, Z., Liu, H., Davuluri, R. V. (2021). DNABERT: pre-trained Bidirectional Encoder Representations from Transformers model for DNA-language in genome. Bioinformatics 37, 2112–2120.
[188] Kim, M.-S., Mun, S. et al. (2021). Spermidine-induced recovery of human dermal structure and barrier function. Communications Biology 4:71.
[189] Kim, B.-S., Choi, S. et al. (2023). Clinical efficacy of EPI-7 postbiotic in dermal aging — a randomized controlled trial. International Journal of Molecular Sciences 24(5):4634.
[190] Lagier, J.-C., Dubourg, G., Million, M. et al. (2018). Culturing the human microbiota and culturomics. Nature Reviews Microbiology 16, 540–550.
[191] LG H&H (2025). LG Household & Health Care — oral microbiome research MOU disclosure. LG H&H press, 2025. [LG H&H, 2025]
[192] Mun, S., Kim, M.-S. et al. (2025). FACE-LINK: A 950-subject Korean facial skin microbiome cohort for personalized cosmetic development. Frontiers in Cellular and Infection Microbiology, 2025. [Mun et al., 2025]
[193] Parallel Health (2024). Parallel Health — phage cocktail for skin microbiome modulation. Parallel Health product disclosures, 2024. [Parallel Health, 2024]
[194] Pfizer (2025). Pfizer × XtalPi AI partnership expansion. Pfizer press, 2025. [Pfizer, 2025]
[195] Ren, F., Aliper, A., Chen, J. et al. (2024). A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models (rentosertib). Nature Biotechnology 42, 1158–1167.
[196] S-Biomedic (2024). S-Biomedic — engineered C. acnes expressing RoxP for sebum redox modulation. S-Biomedic disclosure, 2024. [S-Biomedic, 2024]
[197] Seres Therapeutics (2024). VOWST (SER-109) — first FDA-approved oral microbiome therapeutic commercial update. Seres Therapeutics press, 2024. [Seres Therapeutics, 2024]
[198] Takei, K., Mitoma, C. et al. (2015). Galactomyces ferment filtrate as an aryl hydrocarbon receptor agonist restoring filaggrin expression. Experimental Dermatology 24, 686–691.
[199] Unilever Beauty & Wellbeing (2025). SXSW 2025 — AI/ML/data behind Unilever's latest launches. Unilever news, Mar 2025. [Unilever, 2025-SXSW]
[200] ZOE Health (2024). ZOE PREDICT — nutritional intervention based on microbiome and metabolic phenotyping. Nature Medicine, 2024. [ZOE, 2024]
[201] Novo Nordisk (2024). Novo Nordisk × Cradle — generative protein design partnership announcement. Novo Nordisk press, Nov 2024. [Novo Nordisk, 2024]